13th May 2015 08:36
LONDON (Alliance News) - Oxford Pharmascience Group PLC Wednesday said it had received positive results from a pilot study comparing its OXPzero Naproxen anti-inflammatory treatment with standard US and EU naproxen treatment, and it is now moving to a proof of concept study that compares the extent of gastroduodenal irritation between the two.
In a statement, the pharmaceutical company focused on redeveloping medicines to make them safer and easier to take said the pilot comparative pharmacokinetic study showed OXPzero Naproxen (OXP005) demonstrated an immediate release profile and bioequivalence to the standard naproxen treatment based on mean values.
OXP005 delivers 250 milligrammes of reduced gastric irritation naproxen via the company's patent protected OXPzero technology.
"These pilot PK study results demonstrate that, based on mean values, OXP005 is bioequivalent to Naprosyn and therefore the company is progressing to a proof of concept endoscopy study comparing the extent of gastroduodenal irritation between the OXP005 and Naprosyn. Dosing for this study is on track to start imminently with approvals required for the study in place and potential study subjects identified," the company said.
Oxford Pharmascience shares were up 0.1% at 10.38 pence Wednesday morning.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group